Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week study of mometasone furoate/formoterol versus mometasone furoate in persistent asthma previously treated with high-dose inhaled corticosteroids
2005-005910-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of mometasone and formoterol in asthma (3 arms), sponsored by Merck & Co. Primary endpoint: FEV1 AUC (0-12 hour) change from baseline to Week 12. Started Aug 2006; status: completed.
02
Drugs
mometasoneformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2005-005910-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005910-20.